Journal Article

Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy

Renzo Mignani, Sandro Feriozzi, Antonio Pisani, Antonio Cioni, Cristina Comotti, Maria Cossu, Annalisa Foschi, Antonio Giudicissi, Eliana Gotti, Vito Antonio Lozupone, Francesco Marchini, Fabrizio Martinelli, Francesco Bianco, Vincenzo Panichi, Deni Aldo Procaccini, Elena Ragazzoni, Andrea Serra, Fausto Soliani, Letizia Spinelli, Giacomo Torti, Massimiliano Veroux, Bruno Cianciaruso and Leonardo Cagnoli

in Nephrology Dialysis Transplantation

Published on behalf of European Renal Association - European Dialysis and Transplant Assoc

Volume 23, issue 5, pages 1628-1635
Published in print May 2008 | ISSN: 0931-0509
Published online December 2007 | e-ISSN: 1460-2385 | DOI: http://dx.doi.org/10.1093/ndt/gfm813
Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy

Show Summary Details

Preview

Background. In Fabry disease, end-stage renal disease (ESRD) and severe neurologic and cardiac complications represent the leading causes of late morbidity and mortality. A comprehensive Italian nationwide survey study was conducted to explore changes in cardiac status and renal allograft function in Fabry patients on renal replacement therapy (RRT) and enzyme replacement therapy (ERT).

Methods. This study was designed as a cross-sectional survey study with prospective follow-up. Of the 34 patients identified via searches in registries, 31 males and 2 females who received RRT and ERT (agalsidase beta in 30 patients, agalsidase alpha in 3) were included. Left ventricular mass index (LVMI), interventricular septal thickness at end diastole (IVSD), left ventricular posterior wall thickness (LVPWT) and renal allograft function were assessed at ERT baseline and subsequently at yearly intervals.

Results. The patients in the dialysis and transplant groups had been started on dialysis at age 42.0 and 37.1 years (mean), respectively, and patients in the transplant group received their renal allograft at age 39.8 years (mean). The mean age at the start of ERT was similar, 44.1 and 44.6 years, respectively. The mean RRT follow-up was 61.1 and 110.6 months for dialysis and transplant patients, respectively, whereas the ERT duration was 45.1 and 48.4 months, respectively. Cardiac parameters increased in dialysis patients. In transplant patients, mean LVMI seemed to plateau during agalsidase therapy at a lower level as compared to baseline. Decline in renal allograft function was relatively mild (−1.92 ml/min/year). Agalsidase therapy was well tolerated. Serious ERT-unrelated events occurred more often in the dialysis group.

Conclusions. Kidney transplantation should be the standard of care for Fabry patients progressing towards ESRD. Transplanted Fabry patients on ERT may do better than patients remaining on maintenance dialysis. Larger, controlled studies in Fabry patients with ESRD will have to demonstrate if ERT is able to change the trajectory of cardiac disease and can preserve graft renal function.

Keywords: agalsidase; dialysis; end-stage renal disease; enzyme replacement therapy; Fabry disease; transplantation

Journal Article.  4936 words.  Illustrated.

Subjects: Nephrology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.